Molecular structure of Ataciguat, CAS Number: 254877-67-3
Ataciguat (CAS 254877-67-3)
See product citations (1)
Alternate Names:
5-Chloro-2-[[(5-chloro-2-thienyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide
Application:
Ataciguat is a novel anthranilic acid derivative capable of activating the oxidized form of sGC
CAS Number:
254877-67-3
Molecular Weight:
576.49
Molecular Formula:
C21H19Cl2N3O6S3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ataciguat is a compound that has research interest for its role in modulating the soluble guanylate cyclase (sGC) pathway. This pathway is integral in various biological processes, including vascular function and intracellular signaling. As such, Ataciguat is used to study the regulation of sGC and the downstream effects of its activation or inhibition. Researchers explore how altering the sGC pathway with Ataciguat can affect cellular responses to nitric oxide, which is known to be a key signaling molecule. The compound is also used in the study of cyclic guanosine monophosphate (cGMP)-dependent processes, as sGC is a major source of cGMP in cells. Through such studies, Ataciguat aids in the understanding of intracellular signal transduction mechanisms and the function of cGMP as a second messenger.
Ataciguat (CAS 254877-67-3) References
- Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. | Zhou, Z., et al. 2008. Am J Physiol Heart Circ Physiol. 295: H1763-71. PMID: 18757489
- The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. | Weissmann, N., et al. 2009. Am J Physiol Lung Cell Mol Physiol. 297: L658-65. PMID: 19617308
- Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. | Schäfer, A., et al. 2010. Diabetes. 59: 2001-9. PMID: 20522591
- Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. | Schäfer, A., et al. 2010. Pharmacol Res. 62: 432-8. PMID: 20600916
- Direct fusion of subunits of heterodimeric nitric oxide sensitive guanylyl cyclase leads to functional enzymes with preserved biochemical properties: evidence for isoform specific activation by ciguates. | Haase, N., et al. 2010. Biochem Pharmacol. 80: 1676-83. PMID: 20797390
- Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. | Fraccarollo, D., et al. 2014. Basic Res Cardiol. 109: 421. PMID: 24907870
- Delayed phospholamban phosphorylation in post-conditioned heart favours Ca2+ normalization and contributes to protection. | Inserte, J., et al. 2014. Cardiovasc Res. 103: 542-53. PMID: 25020913
- The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies. | Sharina, IG., et al. 2015. Br J Pharmacol. 172: 2316-29. PMID: 25536881
- Selective inhibitors of trypanosomal uridylyl transferase RET1 establish druggability of RNA post-transcriptional modifications. | Cording, A., et al. 2017. RNA Biol. 14: 611-619. PMID: 26786754
- Comparative Relaxant Effects of Ataciguat and Zaprinast on Sheep Sphincter of Oddi. | Çakmak, E., et al. 2016. Balkan Med J. 33: 453-7. PMID: 27606143
- In Endothelial Cells, the Activation or Stimulation of Soluble Guanylyl Cyclase Induces the Nitric Oxide Production by a Mechanism Dependent of Nitric Oxide Synthase Activation. | Martinelli, AM., et al. 2018. J Pharm Pharm Sci. 21: 38-45. PMID: 29448976
- Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). | Hahn, MG., et al. 2021. J Med Chem. 64: 5323-5344. PMID: 33872507
- Implications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction. | Inserte, J., et al. 2021. JACC Basic Transl Sci. 6: 567-580. PMID: 34368505
- Design, synthesis and biological evaluation of new 3,4-dihydroquinoxalin-2(1H)-one derivatives as soluble guanylyl cyclase (sGC) activators. | Kintos, DP., et al. 2022. Heliyon. 8: e11438. PMID: 36387474
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ataciguat, 5 mg | sc-214560 | 5 mg | $403.00 |